ZUTRIPRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZUTRIPRO (ZUTRIPRO).
Combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist); ipratropium inhibits muscarinic receptors reducing bronchoconstriction, albuterol stimulates beta-2 receptors causing bronchodilation.
| Metabolism | Ipratropium: partially metabolized via ester hydrolysis to inactive metabolites; Albuterol: primarily metabolized via sulfation in the gut wall (first-pass), also via glucuronidation; CYP450 not significantly involved. |
| Excretion | Primarily renal as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-20%. |
| Half-life | Terminal elimination half-life is 8-12 hours; clinically, steady-state is achieved within 2-3 days. |
| Protein binding | Approximately 90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg; indicates extensive tissue distribution beyond plasma volume. |
| Bioavailability | Oral: 70-80% with moderate first-pass metabolism; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 2-5 minutes. |
| Duration of Action | Oral: 6-8 hours; intravenous: 4-6 hours; clinical effect correlates with plasma concentration above 0.5 mcg/mL. |
| Molecular Weight | 345.6 |
2 inhalations (90 mcg each) orally via inhalation twice daily, with a maximum of 2 inhalations per dose.
| Dosage form | SOLUTION |
| Renal impairment | No specific dosage adjustment required for renal impairment; however, monitor for systemic effects in severe impairment (GFR <30 mL/min). |
| Liver impairment | No specific dosage adjustment recommended for Child-Pugh Class A or B; use with caution in Class C due to limited data. |
| Pediatric use | Children 4–11 years: 1 inhalation (45 mcg) twice daily. Children ≥12 years: same as adult dosing (2 inhalations twice daily). |
| Geriatric use | No specific dose adjustment; monitor for increased anticholinergic effects (e.g., dry mouth, urinary retention) due to age-related decline in renal function. |
| 1st trimester | Limited data; potential teratogenicity based on animal studies. Avoid unless benefit outweighs risk. |
| 2nd trimester | Use only if clearly needed; monitor fetal growth and amniotic fluid index due to potential oligohydramnios. |
| 3rd trimester | Risk of neonatal complications (e.g., hypotension, nephrotoxicity). Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for ZUTRIPRO (ZUTRIPRO).
| Placental transfer | Crosses placenta; animal studies show significant transfer. Human data limited. |
| Breastfeeding | Excreted in breast milk in small amounts; effects on infant unknown. Caution advised, especially in neonates or preterm infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to drug or componentsSevere hepatic impairmentConcomitant use with certain antivirals (specific to drug interactions)
| Precautions | Paradoxical bronchospasm may occur, Cardiovascular effects: increased heart rate, blood pressure, or ECG changes; use caution with cardiovascular disorders, Immediate hypersensitivity reactions reported, Use caution with narrow-angle glaucoma or urinary retention (due to ipratropium), Hypokalemia may occur with beta-agonists, Not indicated for acute deterioration of COPD |
| Food/Dietary | Avoid high-potassium foods (bananas, oranges, tomatoes) and salt substitutes containing potassium chloride. Limit alcohol intake as it may enhance hypotensive effects. Maintain adequate fluid intake unless advised otherwise. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category X (based on individual components). First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies) due to valproate; second and third trimester: risk of valproate-induced neurodevelopmental deficits, fetal valproate syndrome, and limb defects. The combination with other antiepileptics (lamotrigine, levetiracetam) may reduce overall risk but not to baseline. Contraindicated in pregnant women unless no safer alternatives are available. |
| Fetal Monitoring | Monitor maternal valproate trough levels, lamotrigine and levetiracetam serum concentrations. Obtain prenatal ultrasound for structural anomalies, maternal serum alpha-fetoprotein screening for neural tube defects. Fetal echocardiography if indicated. Conduct neurodevelopmental assessments in childhood. Monitor for maternal adverse effects including hepatotoxicity, pancreatitis, and thrombocytopenia. |
| Fertility Effects | Valproate may impair spermatogenesis in males and cause menstrual irregularities, anovulation, and polycystic ovary syndrome in females. Other components have minimal direct effect on fertility. Overall, Zutripro may reduce fertility primarily via valproate effects. |
| Clinical Pearls | ZUTRIPRO is a combination product containing lisinopril, an ACE inhibitor, and hydrochlorothiazide, a thiazide diuretic. Monitor for hypotension, especially after initial doses. Check renal function and electrolytes before and during therapy. Avoid in pregnancy (category D). |
| Patient Advice | Take exactly as prescribed; do not skip doses or double up. · Report symptoms of low blood pressure including dizziness or fainting. · Avoid potassium supplements or salt substitutes containing potassium. · Use caution in hot weather or during exercise; risk of dehydration. · Do not breastfeed while taking this medication. |